EUCTR2015-002714-72-DE进行中（未招募）1 期
A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer.(GeparNuevo) - GeparNuevo
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Written informed consent for all study according to local regulatory requirements prior to beginning specific protocol procedures.
- •2.Complete baseline documentation must be sent to GBG Forschungs GmbH.
- •3.Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.
- •4.Tumor lesion in the breast or the nodes must be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion.
- •5.Patients must be in the following stages of disease:
- •-cT1b - cT4a-d irrespective of nodal involvement.
- •In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.
- •6. Triple negative disease with centrally confirmed ER negative/PR negative/HER-2 negative, and centrally confirmed Ki-67 value. ER negative is defined as <1%, PR negative is defined as <10% stained cells and HER2-negative is defined as either IHC 0/1+ or IHC 2+ and in-situ hybridisation (ISH) of either ratio <2.0 or less than 6 copies of HER2 per tumor cell. Stromal TILs will be evaluated in three groups: low immune infiltrate (0-10% stromal TILs), intermediate immune infiltrate (11-59% stromal TILs), LPBC 60-100% stromal TILs. PD-L1 status and other predefined markers will be prospectively assessed during the study. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization.
- •7.Age ? 18 years.
- •8.ECOG Performance status 0-1.
- •9.Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. Results must be above the normal limit of the institution.
- •10.Laboratory requirements:
- •-Absolute neutrophil count (ANC) ? 2.0 x 109 / L and
- •-Platelets ? 100 x 109 / L and
- •-Hemoglobin ? 10 g/dL (? 6.2 mmol/L)
- •Hepatic function
- •-Total bilirubin < 1.5x UNL and
- •-ASAT (SGOT) and ALAT (SGPT) ? 1.5x UNL and
- •-Alkaline phosphatase ? 2.5x UNL.
- •Renal Function
- •-< 1.25x ULN creatinine
- •Thyroid function
- •-FT3 within local laboratory normal range
- •-FT4 within local laboratory normal range
- •-TSH within local laboratory normal range
- •11.Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: =60 years old and no menses for =1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
- •12.Complete staging work-up within 3 months prior to randomization. All patients must have had breast imaging by breast ultrasound plus either bilateral mammography or breast MRI (one of those =21 day). All patients must have had chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan (according to guidelines). In case of positive bone scan, bone X-ray is mandatory. Other tests may be performed as clinically indicated.
- •13.Patients must be available and compliant for central diagnostics, treatment and follow-up.
排除标准
- •1.Prior chemotherapy for any malignancy.
- •2.Prior radiation therapy for breast cancer.
- •3.Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment.
- •4.Inadequate general condition (not fit for dose-dense, dose-intensified anthracycline-taxane-targeted agents-based chemotherapy).
- •5.Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer).
- •6.Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >140 / 90 mm Hg under treatment with at maximum two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
- •7.Mean QT interval corrected for heart rate (QTc) =470 ms calculated from 3 electrocardiograms (ECGs) using Bazett’s Correction
- •8.Active or prior documented inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis)
- •9.History of primary immunodeficiency
- •10.History of allogeneic organ transplant
- •11.Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
- •12. Known history of previous clinical diagnosis of tuberculosis
- •13.Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving MEDI4736
- •14.Autoimmune disease and conditions (i.e. inflammatory bowel disease)
- •15.History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
- •16.Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- •17.Pre-existing motor or sensory neuropathy of a severity ? grade 2 by NCI-CTC criteria v 4.0.
- •18.Currently active infection.
- •19.Incomplete wound healing or unhealed bone fracture.
- •20.Definite contraindications for the use of corticosteroids
- •21.Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol;
- •22.Concurrent treatment with:
- •- chronic corticosteroids prior to study entry with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or equivalent corticosteroid.
- •- other immunosuppressive medication (e.g. low dose MTX)
- •- sex hormones (including hormonal contraception) prior treatment must be stopped before study entry.
- •- other experimental drugs or any other anti-cancer therapy.
- •23.Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.
- •24.Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736
- •25.Male patients.
研究者
相似试验
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancerISRCTN30851756VU University Medical Center (The Netherlands)200
进行中（未招募）
不适用
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer - GeparSixtopatients with triple-negative breast cancer, patients with HER2-positive early breast cancerMedDRA version: 14.1Level: LLTClassification code 10021976Term: Inflammatory breast cancer stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10063104Term: Tubular breast cancer stage IISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10028061Term: Mucinous breast cancer stage IISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10063105Term: Tubular breast cancer stage IIISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 100000004864EUCTR2011-000553-23-DEGerman Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
进行中（未招募）
1 期
A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)EUCTR2012-000091-41-GBniversity College London57
已完成
2 期
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple MyelomaNL-OMON36688HOVO110
进行中（未招募）
不适用
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancerMetastatic breast cancerEUCTR2005-005581-36-ATSchering AG72